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The Danish Aspect
Nils Thorm Milmana, d, Frank Vinholt Schioedta, Anders Ellekaer Junkerb, 
 Karin Magnussenc
Abstract
This paper outlines the Danish aspects of HFE-hemochromatosis, 
which is the most frequent genetic predisposition to iron overload 
in the five million ethnic Danes; more than 20,000 people are ho-
mozygous for the C282Y mutation and more than 500,000 people are 
compound heterozygous or heterozygous for the HFE-mutations. The 
disorder has a long preclinical stage with gradually increasing body 
iron overload and eventually 30% of men will develop clinically overt 
disease, presenting with symptoms of fatigue, arthralgias, reduced li-
bido, erectile dysfunction, cardiac disease and diabetes. Subsequently 
the disease may progress into irreversible arthritis, liver cirrhosis, 
cardiomyopathy, pancreatic fibrosis and osteoporosis. The effective 
standard treatment is repeated phlebotomies, which in the preclinical 
and early clinical stages ensures a normal survival rate. Early detec-
tion of the genetic predisposition to the disorder is therefore important 
to reduce the overall burden of clinical disease. Population screening 
seems to be cost-effective and should be considered.
Keywords: Arthritis; Diabetes mellitus; Hemochromatosis type 1; 
HFE-associated hemochromatosis; Hereditary hemochromatosis; 
Hepatocellular carcinoma; Iron overload; Liver cirrhosis
Introduction
Genetic hemochromatosis is the term for mutations in vari-
ous genes, all of which produce an increased intestinal iron 
uptake, which in the long term may cause accumulation of 
iron in the body organs. Genetic hemochromatosis is divided 
into two main groups: HFE-hemochromatosis and non-HFE-
hemochromatosis. Among people of Northwestern European 
descent including ethnic Danes, HFE-hemochromatosis is by 
far the most common, while non-HFE hemochromatosis oc-
curs sporadically [1].
The Danish National Board of Health in 2017 assigned 
the handling (evaluation, diagnosis and treatment) of patients 
with hemochromatosis to the specialty of gastroenterology and 
hepatology thereby terminating many years of frustration in 
these “homeless” patients, who, due to their plethora of symp-
toms, are referred from one specialty to another in order to 
obtain a diagnosis. This review is based on the Danish Na-
tional Guidelines for HFE-hemochromatosis elaborated by the 
Danish Society for Gastroenterology and Hepatology [2]. The 
figures and text boxes are reproduced with permission from the 
Danish medical journal Ugeskrift for Laeger [3].
HFE-Associated Hemochromatosis
HFE-associated hemochromatosis is due to mutations, or vari-
ants, on the HFE-gene located on chromosome 6p. Most pa-
tients with clinical hemochromatosis are homozygous for the 
Cys282Tyr (C282Y) mutation, but other mutations such as 
His63Asp (H63D) and Ser65Cys (S65C) occur in many peo-
ple. In ethnic Danes, the allele frequency of C282Y is 5.6%, of 
H63D 12.8% and of S65C 1.8%, respectively. The frequency 
of heterozygosity is the allele frequency multiplied by two (i.e. 
12.2% for C282Y, 25.6% for H63D and 3.6% for S65C). The 
mutations and the predisposition to disease are inherited in an 
autosomal recessive way [4].
Prevalence
HFE-hemochromatosis is defined by the presence of ho-
mozygosity or compound heterozygosity for one or more of 
the known HFE-mutations. HFE-hemochromatosis is the 
most common genetic predisposition to iron overload disease 
among ethnic Danes and in people of Northern European de-
scent [5]. In addition, homozygosity for the C282Y mutation is 
the leading cause of clinical hemochromatosis in ethnic Danes, 
that is more than 95% of patients with clinical hemochromato-
sis have this mutation [6]. Population studies have shown that 
among ethnic Danes, 0.4%, or 1 in 250, are C282Y homozy-
gous equivalent to approximately 20,000 people in Denmark. 
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In addition, more than 13% are heterozygous for C282Y and/
or compound heterozygous for C282Y/H63D (1.4%), C282Y/
S65C (0.1%) or H63D/S65C (0.4%) [7]. Based on these fig-
ures, the genetic prevalence of HFE-hemochromatosis among 
ethnic Danes is probably even higher than 0.4% and more than 
500,000 people are compound heterozygous or heterozygous 
for the HFE-mutations [7]. In comparison, the UK Biobank 
Study examining more than 450,000 individuals of European 
descent found a prevalence of C282Y homozygosity of 0.6%, 
or 1 in 156 and a prevalence of C282Y heterozygocity of 
14.3% [8].
Pathogenesis
High concentrations of iron in the cells and tissues will through 
the Fenton reaction trigger the formation of free hydroxyl radi-
cals, which are toxic to the cells and can cause DNA damage 
and cell death with subsequent fibrosis and tissue remodeling 
[9, 10]. The pathogenetic mechanisms by which the mutated 
HFE-gene product afflicts the iron homeostasis are not fully 
understood. Hepcidin, which is produced in the liver, is the 
“master regulator” of body iron homeostasis, and its main task 
is to inactivate ferroportin [1]. Ferroportin has an important 
position in the regulation of iron transport out through the 
cell membrane (efflux) in enterocytes, hepatocytes and mac-
rophages. Normal HFE- and transferrin receptor-2 complexes 
on the cell membrane of the hepatocytes stimulate the produc-
tion/activation of hepcidin, which subsequently inhibits in-
testinal iron uptake. Conversely, iron deficiency leads to a re-
duced production of hepcidin, which causes an increased iron 
uptake [11]. In hemochromatosis, because of a defective HFE-
complex, the production/activation of hepcidin is reduced, re-
sulting in an increased intestinal iron uptake, which is largely 
independent of the body’s iron status. HFE-hemochromatosis 
is thus characterized by a low plasma concentration of hepci-
din termed “hepcidin insufficiency” [1, 11].
The increased iron absorption results in a high serum or 
plasma iron and a high serum or plasma transferrin saturation. At 
transferrin saturation values > 60%, non-transferrin-bound iron 
occurs in plasma, which is readily taken up by the cells in various 
organs (e.g. liver, pancreas, heart and endocrine organs). How-
ever, one exception is the macrophages, which typically contain 
less iron than macrophages in normal control persons [11].
Intracellular iron accumulation triggers oxidative stress, 
DNA damage, cellular necrosis and over time fibrosis. This 
development is typically seen in the liver, where initial fibrosis 
may eventually progress into cirrhosis [9, 10].
Estimation of Body Iron Status
The serum or plasma ferritin concentration is presently the best 
biomarker we have for the body’s iron content, with 1 µg/L 
corresponding to body iron reserves of 7 - 7.5 mg, that is a fer-
ritin of 1,000 µg/L corresponds to an iron excess of 7.0 - 7.5 
g [1, 12, 13].
The serum transferrin saturation percentage is an indica-
tor of the iron content of the blood and the iron supply to the 
organs and helps classify the type of genetic hemochromatosis 
[11, 14]. A high serum transferrin saturation is usually the first 
indicator of HFE-hemochromatosis and can be present, even 
though serum ferritin is still within the normal range. Ferritin 
gradually increases later in the course of the disease. A fasting 
transferrin saturation of ≥ 45% is defined as being elevated 
[15, 16] and should trigger a control measurement and an ad-
ditional measurement of serum ferritin. If the saturation in two 
consecutive measurements is ≥ 45% and/or ferritin is elevated 
(≥ 200 µg/L in women, ≥ 300 µg/L in men), the person should 
be examined for the most common HFE-mutations C282Y, 
H63D and S65C.
Penetrance
The penetrance of the HFE-mutations depends on gender and 
age plus the interaction between the HFE-mutations and the 
composition of the other genes that control the body iron up-
take [7]. In addition, external factors such as the iron content 
of the diet, the composition of the diet, that is the balance 
between promoters and inhibitors of iron absorption, alcohol 
consumption, intake of iron supplements and vitamin C (ascor-
bic acid) [14] as well as blood donations [12, 13] will affect 
the iron homeostasis and the penetrance [17]. The penetrance 
is moderate in premenopausal women, because approximate-
ly 50% of women of reproductive age in Denmark and other 
Northern European countries have low body iron reserves 
[18], mainly due to blood losses at menstruations and child-
births [19] but also due to a relatively low dietary iron intake 
when compared to the recommended intake [20]. However, 
after the menopause, the penetrance increases significantly in 
women. A distinction is made between a preclinical stage in 
which the person, despite a moderate iron overload, does not 
have symptoms, and a clinical stage with greater iron excess, 
which causes symptoms from various organs.
Biochemical penetrance
Biochemical penetrance is defined as an increased fasting 
transferrin saturation ≥ 45% and an elevated serum ferritin ≥ 
200 µg/L in women and ≥ 300 µg/L in men. The biochemical 
penetrance among C282Y homozygous Danish men is high: 
94% have serum ferritin ≥ 300 µg/L, and 44% have values 
> 800 µg/L. Among C282Y/H63D compound heterozygotes, 
penetrance is 1-2% [7]. Among H63D homozygotes, 16% 
have increased transferrin saturation and 29% have increased 
ferritin [21]. High biochemical penetrance is also seen in other 
populations of Northwestern European descent [22].
Clinical penetrance
Clinical penetrance is defined as biochemical penetrance plus 
symptoms and/or organ dysfunction. The clinical penetrance is 
high in men and lower in women. In a population of more than 
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31,000 40-69-year-old persons of Northern European descent, 
203 were C282Y homozygous. Among these, 28.4% of men 
and 1.2% of women had iron overload disease [23]. Among 
C282Y/H63D compound heterozygotes, 1.2% of men (1 out of 
82) had iron overload disease compared to none of women (0 
out of 95) [22]. In general, C282Y/H63D compound heterozy-
gotes are at low risk of hemochromatosis-related morbidity 
[8, 24]. Among H63D homozygotes, 6.7% have iron overload 
disease [21].
The UK Biobank Study showed that in a large commu-
nity sample of European descent, during a lifetime, C282Y ho-
mozygosity is associated with substantial clinically diagnosed 
morbidity in both men and women [8]. C282Y homozygous 
men aged 40 - 70 years (n = 1,294) had a significantly higher 
prevalence of liver disease, rheumatoid arthritis, osteoarthritis, 
osteoporosis and diabetes mellitus, compared to men without 
C282Y mutations (n = 175,539) (P < 0.001). In women aged 
40 - 70 years (n = 1,596) C282Y homozygosity was associated 
with osteoarthritis (P < 0.001) [8].
C282Y homozygous men (n = 1,312) aged 60 - 70 years 
had an increased likelihood of reporting chronic pain, frailty and 
diagnoses of polymyalgia rheumatica and sarcopenia, compared 
to the wild-type genotype. C282Y homozygote women (n = 
312) aged 65 - 70 were more likely to be frail and have chronic 
knee, hip, and back pain. Overall, 1.5% of frail men and women 
in the 65-70-year age group were C282Y homozygous [25].
The overall penetrance (i.e. having a diagnosis of hemo-
chromatosis, liver disease, rheumatoid arthritis, osteoarthritis 
or diabetes mellitus) was 38% in C282Y homozygous men, 
compared with 16% in men with no C282Y mutations (i.e. an 
excess morbidity of 22%). In women, the respective figures 
were 27% versus 17% (i.e. an excess morbidity of 10%) [8].
Symptoms
Persons with HFE-hemochromatosis are often discovered ran-
domly in connection with routine blood sampling and approxi-
mately 75% are asymptomatic at the time of diagnosis [1, 7]. 
Most persons have no symptoms in the early stage of the dis-
ease. With increasing iron accumulation in various tissues and 
organs, the patients develop an increasing burden of symptoms 
and risk of organ involvement [26, 27] (Table 1). Thus, the 
clinical picture will vary depending on how early or how late 
the diagnosis is made and how early or how late iron-depletion 
treatment is started.
Symptoms are most often seen after the age of 30 years 
in men and after the menopause in women. Frequent onset 
symptoms are fatigue, arthralgias, abdominal pain as well as 
decreased libido and erectile dysfunction in men. In a Danish 
study of 179 patients, the first symptoms were fatigue (80%), 
arthralgias (65%) and decreased libido (40%) [27]. In a Nor-
wegian study, the most common symptoms were also fatigue 
(46%), arthralgias (44%) and decreased libido (26%) [28]. To-
gether, these symptoms have a negative impact on the quality 
of life. As fatigue is also a well-known symptom of iron defi-
ciency, some patients start to take iron tablets either on their 
own initiative or at the recommendation of their doctor, with-
out prior examination of their iron status [28, 29].
Organ Involvement
Liver
The excess iron predominantly accumulates in the hepato-
cytes. The first sign of liver dysfunction is persistently, mildly 
to moderately elevated liver enzymes alanine aminotransferase 
and aspartate aminotransferase. At ferritin concentrations 
above 700 - 800 µg/L, liver fibrosis begins to develop [26, 29]. 
If iron depletion treatment (phlebotomy) is not initiated, iron 
accumulation increases and the fibrosis may progress into liver 
cirrhosis, which subsequently may be complicated by hepatic 
insufficiency and hepatocellular carcinoma (HCC) [30]. De-
velopment of liver cirrhosis may also be triggered by other 
hepatic co-morbidities, such as alcoholic liver disease or viral 
hepatitis [30]. Cirrhosis is seen in patients with high ferritin 
concentrations above 1,000 µg/L. A ferritin level below 1,000 
µg/L has a negative predictive value of 95% in the diagnosis of 
cirrhosis. Among randomly selected patients with liver cirrho-
sis, the prevalence of homozygosity for the C282Y mutation is 
10-fold higher than in the background population, emphasiz-
ing the importance of screening all patients with liver cirrhosis 
for hemochromatosis [31].
The clinical and paraclinical pictures of liver cirrhosis as-
sociated with HFE-hemochromatosis do not differ from those 
of cirrhosis due to other causes. In a study of 120 cirrhosis 
patients with hemochromatosis versus 120 patients with cir-
rhosis due to other causes, there was a similar prevalence of 
Table 1.  Patients’ Symptoms and Risk of Organ Involvement
Checking body iron status (serum ferritin and serum transferrin saturation) in patients with:
  Persistent fatigue without any obvious explanation
  Arthralgias, arthritis
  Elevated biochemical liver tests, liver disease
  Diabetes mellitus
  Hypogonadism, erectile dysfunction
  Cardiac disease
  Skin pigmentation
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esophageal varices and splenomegaly [32].
HCC is most often seen in patients with liver cirrhosis but 
may occur in some patients without cirrhosis [33, 34]. Among 
randomly selected patients with HCC, there is a high prevalence 
of C282Y homozygosity of 6-10%, emphasizing that all patients 
with HCC should be screened for hemochromatosis. The risk of 
developing HCC in cirrhosis due to HFE-hemochromatosis is 
20-fold higher than that in the background population.
Extrahepatic cancer
The incidence of other cancers remains controversial. A Swed-
ish study showed no increased incidence of extrahepatic cancer 
in a small series of relatives to patients with hemochromatosis 
[35]. Among Danish C282Y homozygous patients with trans-
ferrin saturation > 60%, an increased incidence of all cancers 
was found in both women and men, compared to the control 
group [36] and the authors of the study recommend that the 
clinician should give increased attention to the occurrence of 
cancer in patients with hemochromatosis [36]. An Australian 
cohort study involving 28,509 persons found an increased risk 
of colorectal cancer in women and men and an increased risk 
of breast cancer in women [37].
Heart
The myocardium is particularly sensitive to iron-induced oxi-
dative stress due to the high content of mitochondria and a 
low content of antioxidants [38, 39]. As a consequence of iron-
induced cardiomyopathy, restrictive diastolic dysfunction and 
various forms of arrhythmias are seen in the initial stage [39, 
40]. Later, patients may develop ventricular arrythmias and 
overt heart failure, which previously was a frequent cause of 
death in patients with hemochromatosis [41].
Joints and bones
Arthritis occurs most frequently in the small finger joints, es-
pecially the second and third metacarpophalangeal joints and 
may display a characteristic radiological pattern [23], but larger 
joints can also be afflicted [27]. Typically, several joints are af-
flicted simultaneously [42, 43]. The pathogenesis remains un-
clear. Various grades of iron deposits are present in the synovial 
membrane but there is no straightforward association between 
the magnitude of iron overload and occurrence of arthritis. Ar-
thritis has been described in several HFE-hemochromatosis 
patients without significant iron overload indicating that other 
factors than just iron per se may be involved [44] (e.g. yet un-
known genetic factors associated with the C282Y mutation).
Osteopenia and osteoporosis occur frequently; among pa-
tients with clinical hemochromatosis 41% have osteopenia and 
25% osteoporosis. The frequency of osteoporosis increases 
with increasing iron overload. The pathogenesis remains un-
clear; both increased bone resorption and reduced bone forma-
tion occur simultaneously [45].
Endocrine glands
Pancreas
Iron-induced destruction of the insulin-producing beta-cells, 
possibly in combination with insulin resistance due to liver 
damage, leads to the development of diabetes mellitus, which 
initially is non-insulin-dependent. As iron overload increases, 
the diabetes will subsequently become insulin-dependent [27, 
37]. The frequency of diabetes depends on how early in the 
course of the disease the diagnosis is made and how soon iron 
depletion treatment is started. In previous patient series with 
clinical hemochromatosis [27, 43], the incidence of diabetes 
was high. The exocrine pancreatic function is not afflicted.
Pituitary gland
Iron can accumulate in all pituitary cells (gonadotropic, thyro-
tropic, somatotropic, lactotropic, corticotropic) and to various 
extents affect the function of these endocrine cells [46]. Panhy-
popituitarism, however, is rare [47]. The gonadotropic cells are 
the first to be afflicted, leading to secondary hypogonadism. 
Hypogonadism in premenopausal women is evidenced by de-
creased levels of luteotropic and follicle stimulating hormone, 
decreased libido and amenorrhea [47]. In men, decreased pro-
duction of luteotropic and follicle stimulating hormone will 
result in a decreased production of testosterone as well as de-
creased spermatogenesis and cause reduced libido and erectile 
dysfunction. Furthermore, hypogonadism contributes to an 
increased risk of osteoporosis.
Thyroid gland
There is often considerable iron accumulation in the thyroid. 
Clinical and subclinical hypothyroidism occurs in patients with 
clinical hemochromatosis, but the prevalence is barely signifi-
cantly increased compared to the background population [48].
Skin
In patients with advanced clinical hemochromatosis, the com-
bination of iron deposition in the skin and concurrent stimu-
lation of the melanin production by melanocytes can lead to 
excess skin pigmentation, most often in the form of a very sun 
tanned or greyish appearance, which in combination with dia-
betes mellitus previously was called “bronze diabetes” [27].
Diagnostic Evaluation and Examinations for 
HFE-Hemochromatosis
A diagnostic and therapeutic algorithm is shown in Figure 1. 
The initial examinations (general clinical examination and 
blood sample analyses) can be performed by all medical doc-
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tors including general practitioners, while more elaborate ex-
aminations should be performed in the specialist departments 
in clinics or hospitals.
Paraclinical Examinations
Liver biopsy with histochemical, semi-quantitative assessment 
or chemical determination of iron content was previously the 
standard diagnostic method in hemochromatosis. Following 
the introduction of the serum ferritin assays and HFE-geno-
typing, liver biopsy is now reserved for those patients where 
there is doubt about the diagnosis, such as in certain types of 
non-HFE hemochromatosis, dysmetabolic iron overload syn-
drome (DIOS), non-alcoholic fatty liver disease (NAFLD) 
[49], as well as some types of alcoholic liver disease present-
Figure 1. Diagnostic and therapeutic algorithm (simplified) in the assessment of HFE-hemochromatosis.
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ing with elevated ferritin and moderate iron overload. How-
ever, patients with DIOS, NAFLD and alcoholic liver disease 
usually have a normal transferrin saturation, but an overlap 
with hemochromatosis is seen in some patients. In addition, 
liver biopsy may be used to assess the degree of fibrosis/cir-
rhosis and the presence of HCC.
Ultrasound scan of the liver is often the first diagnostic 
step,when the patient presents with elevated liver enzymes or 
there is suspicion of liver disease. Ultrasound cannot detect 
iron in liver tissue and therefore cannot be used for the diagno-
sis of iron overload in hemochromatosis [50, 51], but is useful 
for differential diagnostic purposes to exclude other causes of 
elevated liver enzymes and NAFLD. Ultrasound can also be 
used in the diagnosis of liver cirrhosis and HCC.
Ultrasound-based elastography (Fibroscan®) of the liver 
for assessment of fibrosis in hemochromatosis patients has 
only been validated in a few studies [51-53]. Further studies 
are needed to clarify whether this modality can be used in the 
investigation and follow-up of HFE-induced liver fibrosis.
Computed tomography (CT) of the liver can detect iron 
in the liver parenchyma, but the method requires special pro-
gramming of the scanner, is semi-quantitative and has several 
sources of error [54, 55]. After the introduction of magnetic 
resonance imaging (MRI), CT scan is seldom used in the de-
tection of liver iron content. However, focal lesions in the liver 
can be visualized by CT scan.
MRI scan of the liver is, in the experienced setting, a good 
method for quantitative measurement of the liver iron content 
[50, 56, 57]. There exists no common consensus on the meth-
odology, so each center has to develop its own program and 
calibrate their scanner using objects with known iron concen-
trations. In Denmark, this modality is available at radiological 
centers in university hospitals.
MRI scan of the heart can be used to detect iron accumula-
tion in the myocardium [41, 58] and is in Denmark performed 
at radiological centers in university hospitals. The iron content 
can also be assessed by histochemical methods in endomyo-
cardial biopsies [59].
Electrocardiography and echocardiography are used in the 
screening for heart disease caused by HFE-hemochromatosis 
and other iron overload disorders [60]. Echocardiography and 
electrocardiography should always be performed when there 
are symptoms or suspicion of heart disease.
X-ray of the joints is used to evaluate the extent of ar-
thritis. A rheumatological scoring system, based on X-rays of 
hands, wrists, knees and ankles, has been validated in a cohort 
of hemochromatosis patients with arthritis [61].
Dual-energy X-ray absorptiometry (DXA scan) is used to 
determine bone density and examine for osteopenia and osteo-
porosis [62].
Treatment
The standard treatment of HFE-hemochromatosis is simple, 
as the body’s excess iron is removed by repeated lettings of 
whole blood (phlebotomy) [63, 64]. It is an effective and 
low-cost procedure to reduce iron overload and there are few 
side effects. A patient-blinded, randomized study of patients 
with HFE-hemochromatosis and ferritin between 300 - 1,000 
µg/L showed significant improvement in fatigue and cognitive 
scores in patients treated with erythrocyte-apheresis compared 
to patients treated with plasma-pheresis [65].
In normal persons, under conditions with a plentiful iron 
supply, the maximal erythropoietic response to anemia is ap-
proximately a 200% increase over basal erythropoietic rate 
[66]. In hemochromatosis patients, the erythropoiesis usually 
works in a normal way and most patients regain their habitual 
hemoglobin level in a few weeks. Prior to phlebotomy, the he-
moglobin concentration should be checked. There is no con-
sensus on which critical hemoglobin level should trigger post-
ponement of phlebotomy. In Canada and USA, a critical value 
of 110 g/L (6.8 mmol/L) is recommended [17] and in Spain, 
a critical value of 120 g/L (7.4 mmol/L) is used (Milman et 
al, personal communication). When hemoglobin is below 120 
g/L prior to phlebotomy, postponing the procedure should be 
considered until hemoglobin has increased. Subsequently ex-
tend the intervals between blood lettings and/or draw less than 
450 - 500 mL blood at each procedure. The phlebotomy regime 
must be adjusted to the individual patient in order to avoid 
significant side effects, especially fatigue and lack of energy. 
Depending on the hemoglobin concentration, 220 - 300 mg of 
iron is removed by a bloodletting of 450 mL (Table 2).
To the knowledge of the authors no studies have examined 
whether treatment with erythropoietin in order to stimulate 
erythropoiesis in patients with HFE-hemochromatosis may al-
low an increase in the phlebotomy rate in order to enhance the 
rate of body iron depletion.
Newly diagnosed patients start with “induction treat-
ment”, consisting of phlebotomy at 1 - 2 week interval until 
ferritin has dropped to a level between 50 - 100 µg/L (Fig. 2).
The patient then shifts to an individual “maintenance 
treatment” with phlebotomy 2 - 4 times per year, in order to 
maintain the ferritin level at 50 - 100 µg/L and the transferrin 
saturation below 60%. Some especially frail elderly patients 
Table 2.  Treatment of HFE-Hemochromatosis
Induction treatment
  Phlebotomy 300 - 500 mL at 1 - 2 weeks intervals, until serum ferritin is < 100 µg/L
  Check hemoglobin before each phlebotomy and ferritin after every fourth phlebotomy
Maintenance treatment
  Phlebotomy 1 - 4 times per year to maintain ferritin level at 50 - 100 µg/L and transferrin saturation < 60%
  Check hemoglobin, ferritin, and transferrin saturation before and 3 - 4 months after phlebotomy
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with co-morbidities do not tolerate the “standard phlebotomy 
regimen”; in these patients, a modified phlebotomy regimen 
may be required in the induction phase, where less than 450 
- 500 mL blood is drawn and/or the intervals between phle-
botomies may be extended. In the elderly, frail patients, a 
higher ferritin level of 200 - 400 µg/L may be accepted, in 
order to avoid anemia and discomfort due to the phlebotomies. 
In patients with difficult peripheral veins, ultrasound-guided 
venepuncture may be helpful.
In the induction phase the hemoglobin concentration 
should be measured prior to each phlebotomy, while ferritin 
and transferrin saturation are measured at every third to fourth 
phlebotomy. Plasma folate and plasma cobalamin should be 
checked at regular intervals and, if necessary, vitamin supple-
ments with folic acid and vitamin B12 should be given.
In the maintenance phase, the patient should be checked 
with hemoglobin, ferritin and transferrin saturation every third 
to fourth month, and based on the results, a decision is made 
for phlebotomy. Patients should be followed lifelong on an 
out-patient basis.
In many countries, patients with preclinical hemochroma-
tosis and patients with mild symptoms, but without chronic 
disease, are included in the blood donor corps and contribute 
extensively to cover the need for blood [67, 68]. In Denmark, 
there is no consensus on this issue, which is highly required in 
view of the facts that many blood donors actually have hemo-
chromatosis without knowing it, and that many symptom-free 
patients with hemochromatosis become frustrated, because 
their blood is discarded and not used to help other patients.
In patients who do not tolerate phlebotomy, iron-chelating 
treatment with parenteral deferoxamine or oral deferiprone or 
oral deferasirox may be offered [69, 70]. There are ongoing 
clinical studies to assess the iron-chelating effect of deferasirox 
and K-deferasirox in patients with iron overload due to HFE-
hemochromatosis. However, treatment with iron-chelating 
agents is significantly less effective than phlebotomy and may 
in some patients be associated with unpleasant side effects.
Several hepcidin agonists have been developed and are 
currently undergoing clinical trials. Results are pending; hope-
fully they will work and be approved for clinical use, which 
could be a major advance in the treatment of genetic hemo-
chromatosis and other iron overload disorders [71].
Prognosis
A Danish study showed that patients with HFE-hemochroma-
tosis, who are not treated or treated insufficiently, have a lower 
survival rate due to cirrhosis, HCC, cardiomyopathy and dia-
betes than patients receiving adequate iron-depletion treatment 
[72]. C282Y homozygous men with serum ferritin above 1,000 
µg/L have a significantly higher prevalence of chronic fatigue, 
arthritis and liver disease than men without HFE-mutations 
[23]. The ferritin level at the time of diagnosis has prognostic 
significance, since patients with ferritin < 1,000 µg/L have a 
lower mortality rate than patients with ferritin > 2,000 µg/L 
[73, 74].
The earlier the diagnosis is made, the sooner treatment 
with phlebotomy is started; the lower the risk of developing 
organ dysfunction or organ damage is, the higher the survival 
rate will be. Patients in the preclinical stage and patients in the 
clinical stage without permanent organ dysfunction, such as 
Figure 2. A 55-year-old woman with hemochromatosis and liver fibrosis. Due to fatigue, the patient had been taking iron tablets 
for several years without having a checkup of her body iron status. After 22 phlebotomies over a period of 300 days, the iron 
excess was finally removed.
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liver cirrhosis, cardiomyopathy, pancreatic fibrosis and diabe-
tes mellitus, will after adequate treatment have the same sur-
vival rate as the background population [75].
Although, at the time of diagnosis, organ damage, such 
as arthritis, liver cirrhosis, cardiomyopathy, pancreatic fibrosis 
and diabetes mellitus, is present, the patients must be treat-
ed with phlebotomy in order to prevent further deterioration 
of organ function. In most patients, treatment will lead to an 
improvement in organ functions (e.g. in patients with liver fi-
brosis, liver cirrhosis, cardiomyopathy and diabetes) [73-75], 
while arthralgias and arthritis often persist despite adequate 
iron-depletion treatment [42].
The production of gastric acid in the ventricle promotes 
the intestinal uptake of iron. Consequently, both antacids and 
proton pump inhibitors reduce iron uptake. In patients with 
hemochromatosis in the maintenance phase, administration of 
proton pump inhibitors may prolong the phlebotomy intervals 
[76, 77], which can be an advantage for some patients.
Patients with HFE-associated liver cirrhosis and hepatic 
insufficiency can be treated with liver transplantation, which 
“cures” the hemochromatosis, because the transplanted normal 
liver has the wild-type HFE-genotype and normal hepcidin 
production [78, 79]. Patients with life-threatening HFE-associ-
ated cardiomyopathy can benefit from cardiac transplantation 
or implantation of an artificial heart [79].
Diet and Dietary Supplements
In general, the diet of patients with hemochromatosis should 
follow the dietary guidelines of the Danish National Food In-
stitute with regards to macro- and micronutrients, except for 
the iron content of the diet, which should be as low as pos-
sible. The absorption of both heme iron, mainly from meat, 
poultry and guts, and non-heme iron, mainly from vegetable 
food items, is increased in hemochromatosis, despite the pres-
ence of body iron overload. Besides the iron content per se in 
the foods, the balance between enhancers and inhibitors of iron 
absorption in the meal is important. Dietary adjustments can 
have an impact on how frequently the patient must be phlebot-
omized both during the induction and maintenance treatments 
but especially during the latter. However, it is up to the indi-
vidual patient to decide to what extent he/she wants to change 
the diet in order to prolong the phlebotomy intervals. There are 
no controlled studies on the importance of the diet for the iron 
uptake in hemochromatosis, but presumably a carefully com-
posed diet with a low iron content and being rich in inhibitors 
of iron absorption could significantly reduce the intestinal iron 
uptake [80].
Heme iron is absorbed 3 - 4 times better than non-heme 
iron, and in addition, meat and poultry contain the so-called 
“meat factors” that promote the absorption of non-heme iron. 
The meat intake, especially from red beef, which contains a 
high amount of heme iron, should therefore be limited. Vita-
min C promotes iron absorption when consumed with the meal 
and vitamin supplements containing vitamin C must therefore 
be taken between the meals. Alcohol increases the uptake of 
iron from the duodenum significantly when taken with a meal 
[80]. Therefore, the alcohol intake should be limited and pref-
erably consumed between meals and should not exceed the 
recommendations of the Danish National Board of Health, 
which is 14 units/week for men and 7 units/week for women.
Iron absorption is inhibited by phytic acid and phytates 
contained in cereals and bread and by polyphenols or tannins 
contained in tea and coffee. The content of polyphenols in one 
cup of black tea consumed with each meal has been shown to 
inhibit iron uptake and prolong the phlebotomy intervals [81]. 
Likewise, polyphenols are also available in tablets as dietary 
supplements. Calcium and magnesium in milk products also 
inhibit iron absorption and should be taken with meals.
As a consequence of the frequent phlebotomies in the 
induction phase, the body may be derived of protein and vi-
tamins. Vitamin supplements may therefore be needed, espe-
cially folic acid and vitamin B12. Any kind of iron supplements 
including iron fortified foods must be avoided. Multivitamin-
multimineral tablets without iron should be taken between 
meals. Calcium and vitamin D supplements for the prophylax-
is and treatment of osteopenia or osteoporosis should be taken 
with meals. The frequent phlebotomies in the induction phase 
strongly stimulate iron absorption and many patients have an 
induction phase of 6 - 12 months or even longer. Consequently, 
dietary counseling and specific changes in the diet should be 
introduced early in the treatment phase. During the mainte-
nance phase, the focus on the diet may have a positive impact 
on the patient’s sense of control of their own disease and can 
presumably reduce the number of phlebotomies.
Family Screening
When a person (proband) is diagnosed with HFE-hemochroma-
tosis, the closest genetic relatives (i.e. the proband’s biological 
parents, siblings and children) should be examined with HFE-
genotyping as to whether they have inherited the mutation(s). 
Due to the high frequency of C282Y and H63D heterozygosity 
in the Danish population, it is also recommended to examine 
the proband’s partner, when they have children. The examina-
tion of children may be postponed until it is convenient for 
both parents and children or until the children become mature.
Population Screening
Due to the high frequency of homozygosity and compound 
heterozygosity, and the significant long-term effects on health 
and quality of life as last shown in the UK Biobank Study [8], 
it should be considered whether screening of ethnic Danes for 
the HFE-hemochromatosis mutations should be implemented, 
as previously suggested in 1995 [29].
HFE-hemochromatosis meets the World Health Organiza-
tion’s criteria for screening [82] and a study has shown that 
Danes have a very positive attitude towards screening for 
HFE-hemochromatosis [83]. An Australian study has demon-
strated that several modalities of screening appear to be cost-
effective for the society [84, 85].
Early diagnosis and treatment,which could be by blood 
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donation, can save the society for considerable health-related 
costs [85]. Routine measurement of serum ferritin in blood 
donors in order to check their iron status prior to blood dona-
tion could identify many individuals in the preclinical stage. 
Important messages include: 1) HFE-hemochromatosis has 
been in the general health system for many years a disregarded 
genetic disorder/disease and the diagnosis is often made late 
in the clinical stage, implying considerable excess morbidity 
and mortality; 2) Among the five million ethnic Danes, at least 
20,000 are homozygous and at least 500,000 are carriers of the 
HFE-mutations C282Y and H63D; 3) Diagnosis is obtained by 
blood analyses of serum ferritin, serum transferrin saturation 
and genetic testing for HFE-mutations; 4) Early diagnosis and 
treatment with phlebotomy prevent organ damage, increase 
quality of life and ensure normal survival rate; 5) Measurement 
of ferritin and transferrin saturation should be included the bio-
chemical “routine analysis packages” used in the diagnostic 
evaluation of all patients presenting with health problems; 6) 
Persons having hemochromatosis in the preclinical and early 
clinical phase should be accepted as blood donors by the blood 
banks; and 7) Population screening for HFE-hemochromatosis 
appears to be cost-effective and should be considered.
In Denmark, all women are recommended to take iron 
supplements during pregnancy, including the approximately 
400 women with HFE-mutations as well as the additional 
20-30% of women who do not need extra iron. Among Dan-
ish women, more than 90% sooner or later become pregnant. 
Routine measurement of ferritin and transferrin saturation in 
pregnant women at their first check-up in the antenatal clinic 
(in Denmark at the general practitioner) in order to check iron 
status before prescribing iron supplements is recommended by 
the Danish Society of Obstetrics and Gynecology [86], but has 
still not been implemented by the Danish National Board of 
Health. Besides checking for iron deficiency, such a practice 
could identify women being genetically predisposed to HFE-
hemochromatosis in the preclinical stage.
Conclusions
HFE-hemochromatosis is the most common genetic predispo-
sition to disease in ethnic Danes as more than 20,000 individu-
als are homozygous for the C282Y mutation. The disease has a 
long preclinical stage with increasing iron accumulation in the 
body organs and approximately 30% of men develop clinical 
disease over time, while the clinical penetrance is low in pre-
menopausal women but increases after the menopause.
Hemochromatosis is a multifaceted disease, in which the 
initial symptoms are fatigue, arthralgias, decreased libido, 
erectile dysfunction, signs of heart disease and diabetes mel-
litus. Later, organ dysfunction and organ damage occur in the 
form of liver cirrhosis, cardiomyopathy, pancreatic fibrosis 
and osteoporosis. The treatment consists of phlebotomy, which 
during the preclinical stage and in the early clinical stage will 
ensure a normal survival rate. Since the symptoms and organ 
damages are often irreversible, it is important that treatment is 
started early, namely before symptoms and organ dysfunction 
have developed.
Typically, many patients experience a long and confusing 
course in the health system and encounter various doctors and 
various specialties before the diagnosis is confirmed, often in 
an advanced clinical stage. This is evident in the UK Biobank 
Study [8] where only 22% of the men and 10% of the women 
aged 40 - 70 years had been diagnosed with hemochromatosis 
by the end of a 7-year follow-up period. It is therefore im-
portant that the specialties involved in the initial evaluation 
of patients presenting with symptoms, which are compatible 
with hemochromatosis (general practitioners, rheumatologists, 
endocrinologists, gastroenterologists, hepatologists, cardiolo-
gists) are aware of the disease and know how to make the diag-
nosis on a blood sample and then refer the patient to an appro-
priate clinic or hospital for further evaluation. Generally, the 
use of dietary iron supplements and treatment with iron tablets 
must always be based on the presence of iron deficiency, con-
firmed in a blood sample.
The Danish Hemochromatosis Association (Dansk Haemok-
romatose Forening) [87] is a patient-based organization, which 
was founded in 2012 and subsequently has been working to im-
prove and spread the knowlegde about hereditary hemochroma-
tosis both in the society and in the public health system.
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